Pharma & Biotech Global Week in Review 28 Sept 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.


Highlights this week included:

US: CAFC: Patent exhaustion does not apply to genetically engineered seed: Monsanto Co. v. Bowman (Patent Docs) (IPBiz) (Patently-O)

Australia: Divided Senate Committee urges rejection of Gene Patents Bill (Patentology) (BIOtechNOW) ( (IP Whiteboard)


Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.



What the 2001 Doha Declaration changed (KEI)

Health Impact Fund – Raising issues of distribution, IP rights and alliances (IP Watch)

Australia: Divided Senate Committee urges rejection of Gene Patents Bill (Patentology) (BIOtechNOW) ( (IP Whiteboard)

China: Sino-U.S. investment vehicle to bring U.S. medicines into Chinese pharmaceutical market (IP Dragon)

EU: Dawn of a new era? The AG’s opinion in Georgetown and Medeva (The SPC blog)

Hungary: Repeatedly filed request for preliminary injunction – micronized active ingredient (EPLAW)

Indonesia pharma patents and generic manufacture (IP Komodo)

South Africa: Traditional Knowledge Bill debate – your views needed (Afro-IP) (Afro-IP) (Afro-IP)

UK: Second round consultation on Patent Box proposal (including SPCs) ends (The SPC Blog)

US: CAFC: Patent exhaustion does not apply to genetically engineered seed: Monsanto Co. v. Bowman (Patent Docs) (IPBiz) (Patently-O)

US: President’s deficit reduction plan seeks to reduce exclusivity period for biologics and prohibit pay-for-delay deals (Patent Docs)

US: DHHS Secretary Donna Shalala to Rep Jan Schakowsky in 2000, on WHO access to fed funded patent rights (KEI)

US: AMP v USPTO: The latest developments (Patent Law Practice Center)

US: ISIS Pharmaceuticals files patent infringement suit against Santaris based on its sale of drug discovery services and drug candidates including antisense compounds that inhibit beta-catenin production (Patent Docs)

US: False marking claim dismissed for generalised pleading: Simonian v Astellas Pharma (Chicago Intellectual Property Law Blog)



Amoxicillin – India: Japanese pharmaceutical company sues for patent infringement in Delhi to protect its French markets: Astellas Pharma v Micro-Labs (Spicy IP)

Angiomax (Bivalirudin) – US: It ain’t over ‘til it’s over – The ANGIOMAX PTE battle takes yet another new turn (FDA Law Blog)

Eloxatin (Oxaliplatin) – US: Sanofi secures injunction blocking Sun from marketing generic Eloxatin (Patent Docs)

Fentora (Fentalyn) – US: Cephalon files patent infringement suit against Sandoz following Para IV certification (Patent Docs)

Fosamax (Alendronic acid) and Lescol (Fluvastatin) – Spain: Should national nullity proceedings be stayed until parallel EPO opposition proceedings are resolved? (Kluwer Patent Blog)

Gabitril (Tiagabine) – US: Cephalon files suits against Sun Pharma. in New Jersey and Michigan in response to Para IV certification (Patent Docs)

Glivec (Imatinib) – India: Novartis Glivec patent case: preliminary objection (Spicy IP)

Lovenox (Enoxaparin) – US: Momenta files patent infringement complaint against Amphastar in response to impending launch of generic Lovenox (Patent Docs)

Lumigan (Bimatoprost) – US: Validity of Allergan Lumigan patents upheld (Patent Docs)

Nexavar (Sorafenib) – India: Natco pushes ahead with bid to compulsorily licence anti-cancer drug from Bayer (IP Whiteboard)

Nexavar (Sorafenib) – India: Tracking the litigation around Bayer’s Nexavar patent in India (Spicy IP)

PhosLo (Calcium acetate) – US: Fresnenius Medical Care files patent infringement complaints in E D New York and Massachusetts against Invagen in response to Para IV challenge (Patent Docs)

Solodyn (Minocycline) – US: Medicis secures permanent injunction, settling Solodyn dispute with Aurobindo (Patent Docs)

Valsartan – France: Cour d’appel rules on Valsartan SPC: Actavis v Novartis (The SPC Blog)

Xyzal (Levocetirizine dihydrochloride) – US: District Court vacates 30-month stay extension; says stay only applies to ANDAs containing a Paragraph IV certification: Sunovion v Sandoz (FDA Law Blog)

Zyprexa (Olanzapine) – Netherlands: Court of Appeal The Hague holds Lilly’s Olanzapine patent and SPC valid: Eli Lilly v Ratiopharm (EPLAW)

%d bloggers like this: